Blue Jet Healthcare Limited has informed the Exchange about Transcript
BLUEJET · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Blue Jet Healthcare posted Q1 FY26 revenue of Rs. 354.8 crore, up 118% year-on-year and 4% sequentially, with EBITDA at Rs. 121 crore (34% margin) and PAT at Rs. 91.2 crore (25.7% margin). Gross margin dipped sequentially to 48.5% from 55%, attributed to a Rs. 75 crore inventory drawdown (4.4% impact) and product mix shift (2.1%); on a combined Q4+Q1 basis, gross margin stands at 53%. Unit-2 expansion is now fully operational, Unit-3 Mahad is on track for H2 FY26 commissioning with CAPEX revised up to Rs. 300 crore (Rs. 100 crore already spent, Rs. 200 crore more through FY27), and the company plans to add 1,000 KL of capacity over the next 2-3 years. Management highlighted 20 R&D opportunities with 6 in late Phase III or commercial, 45 peptide fragments ready, new contrast media launches slated for H2, and a fund raise under evaluation.
Strong YoY growth, healthy cash position (Rs. 270 crore), and visible order pipeline are positives, but the sequential margin dip and Rs. 200 crore of remaining CAPEX through FY27 may weigh on near-term returns. New launches in contrast media and the upcoming Mahad commissioning in H2 FY26 could be key catalysts for the stock.